Protea, Yale Ink License Agreement for Melanoma Test | GenomeWeb

NEW YORK (GenomeWeb) – Protea Biosciences has licensed a mass spectrometry-based technology from Yale University aimed at improving diagnosis of melanoma.

The Morgantown, West Virginia-based firm is developing a test that will use proteomic mass spec imaging (MSI), pioneered by Yale Dermatology Professor Rossitza Lazova and Protea's Erin Seeley.

According to the partners, the imaging technology allows researchers to identify hundreds of specific proteins in tissue, which can help distinguish between cancerous melanomas and benign moles, also called melanocytic nevi.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.